Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-06
2007-03-06
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004300, C514S866000, C530S303000, C530S399000, C530S808000
Reexamination Certificate
active
10431175
ABSTRACT:
A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.
REFERENCES:
patent: 4608364 (1986-08-01), Grau
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5091173 (1992-02-01), Buultjens et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5374620 (1994-12-01), Clark et al.
patent: 5466670 (1995-11-01), Dunger et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5614219 (1997-03-01), Wunderlich et al.
patent: 5681814 (1997-10-01), Clark et al.
patent: 5756463 (1998-05-01), Arrhenius-Nyberg et al.
patent: 5783556 (1998-07-01), Clark et al.
patent: 5788959 (1998-08-01), Singh
patent: 6559122 (2003-05-01), Oeswein et al.
patent: 123228 (1984-10-01), None
patent: 128733 (1984-12-01), None
patent: 288451 (1988-10-01), None
patent: 440989 (1991-08-01), None
patent: 230869 (1992-09-01), None
patent: 313343 (1995-04-01), None
patent: 0 615 444 (1996-03-01), None
patent: 884053 (1998-12-01), None
patent: WO 87/01038 (1987-02-01), None
patent: WO 91/03253 (1991-03-01), None
patent: WO 91/18621 (1991-12-01), None
patent: WO 93/23071 (1993-11-01), None
patent: WO 94/15584 (1994-07-01), None
patent: WO 94/16722 (1994-08-01), None
patent: WO 95/34318 (1995-12-01), None
patent: WO 96/01124 (1996-01-01), None
patent: WO 96/01125 (1996-01-01), None
patent: WO 98/01161 (1998-01-01), None
patent: WO 98/06423 (1998-02-01), None
patent: WO 99/24063 (1999-05-01), None
Tomas et al., Diabetes, vol. 45, pp. 170-177, Feb. 1996.
Baxter, “The somatomedins: insulin-like growth factors”Advances in Clinical Chemistry25:49-115 (1986).
Binoux, M., “Donnees recentes sur les somatomedines (Insulin-like growth factors)”Annales d'Endocrinologie41:157-192 (1980).
Boulware et al., “Phosphate and Potassium Lowering Effects of Insulin-like Growth Factor-I in Humans: Comparison with Insulin”The Endocrine Society, San Antonio, (74th Annual Meeting) pp. 78:106 (abstract only) Jun. 1992).
Brange, J., “Insulin Preparations”Galenics of Insulin. The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations, New York:Springer-Verlag pp. 17-40 (1987).
Burgess et al., “Characterization of albumin-acacia complex coacervation”Journal of Pharmacy&Pharmacology43 (4):232-236 (Apr. 1991).
Campbell, “The Evolution of Insulin Therapy”Pharmacy Times, Romaine Pierson vol. 59:40-44 (Oct. 1993).
Cheetham et al., “The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus”Clin. Endocrinol. 40:515-522 (1994).
Cheetham et al., “The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type I (Insulin-dependent) Diabetes Mellitus”Diabetologia36:678-681 (1993).
Clemmons and Van Wyk, “Somatomedin: physiological control and effects on cell proliferation”Handbook Exp. Pharmacol. 57:161-208 (1981).
Dodd et al., “Reversible absorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electrostatic interaction”Pharmaceutical Research12(1):60-68 (Jan. 1995).
Dunger et al., “Insulin-like Growth Factors (IGFs) and IGF-I Treatment in the Adolescent With Insulin-dependent Diabetes Mellitus”Metabolism44(10):119-123 (Suppl. 4 1995).
Eizirik et al., “Insulin-Like Growth Factor I Does not Inhibit Insulin Secretion in Adult Human Pancreatic Islets in Tissue Culture”European J. of Endocrinology133(2):248-250 (1995).
Elahi et al., Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in menModern Concepts of Insulin-Like Growth Factors, Spencer, EM, ed., New York:Elsevier Science Publ. Co. pp. 219-224 (1991).
Froesch et al., “Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I”Horm. Res. 42:66-71 (1994).
Fuller et al., “Stimulation of Cardiac Protein Synthesis by Insulin-like Growth Factors”Biochemical Society Transactions19:277S (1991).
Furnsinn et al., “Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats”Endocrinology135(5):2144-2149 (1994).
Galloway and deShazo, “Insulin chemistry and pharmacology; insulin allergy, resistance, and lipodystrophy”Diabetes Mellitus: Theory and Practice, Rifkin and Porte, Jr. eds., Fourth edition, New York:Elsevier, Chapter 29, pp. 497-513 (1990).
Guler et al., “Effects of Insulin-like Growth Factor I in Men”Acta Paediatr. Scand. 367:52-54 (Suppl. 1990).
Guler et al., “Short-term metabolic effects of recombinant human insulin-like growth factory I in health adults”New England J. of Medicine317(3):137-140 (1987).
Gunn et al., “Anabolic steroids do not alter the effect of insulin adn IGF-2 on protein breakdown in L6 muscle cells”Biochemical Archives5:53-59 (1989).
Jabri et al., “Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients”Diabetes43:369-374 (1994).
Jacob et al., “Metabolic Effects of IGF-I and Insulin in Spontaneously Diabetic BB/w Rats”Am. J. Physiol. 260:E262-E268 (1991).
Kerr et al., “Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia”Diabetes: American Diabetes Association(ADA), San Antonio, Texas, Jun. 20-23, 1992 (abstract #225), 52nd Annual Meeting edition 41(supp 1):60A (Jun. 1992).
Kerr et al., “Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans”J. Clin. Invest. 91:141-147 (1993).
Kissel et al., “Applikationsformen des Insulins (Forms of Adminstration of Insulin—English translation provided)”Deutsche Apotheker-Zeitung(Germany) 134(7):25-39 (1994).
Kuzuya et al., “Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes”Diabetes42:696-705 (1993).
Leahy et al., “Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion”Endocrinology126(3):1593-1598 (1990).
Lewitt et al., “Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels”Endocrinology129(4):2254-2256 (1991).
Lieberman et al., “Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans”J. Clin. Endocrinol. and Metab. 75(1):30-36 (1992).
Mathe, G., “Relations of hormones and growth factors at the crossroad of pathogenesis and pharmacotherapeutics. The case of diabetes mellitus”Biomedicine&Pharmacotherapy49(5):221-224 (1995).
Mauk and Mauk, “Interaction between cytochrome b5and human methemoglobin”Biochemistry21(19):4730-4734 (Sep. 14, 1982).
Morrow et al., “Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance”Diabetes-53rd Annual Meeting, Jun. 12-15, 1993 (abstract No. 269) 42:83A (Suppl. 1 1993).
“Quick inventory check: diabetes products”U.S. Pharmacist18(Nov. Suppl.):38-40 (1993).
Quin et al., “Acute Response to Recombinant Insulin-like Growth Factor I in a Patient with Mendenhall's Syndrome”New England J. of Medicine323:1425-1426 (1990).
Randazzo et al., “Characterization of the Growth of Murine Fibroblasts That Express Human Insulin Receptors”Exp. Cell Res. 190(1):31-39 (1990).
Rinderknecht and Humbel, “Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical ch
Oeswein James Q.
Smikahl John R.
Wang Sharon X.
Yeung Douglas A.
Dreger, Esq. Ginger R.
Genentech Inc.
Hasak, Esq. Janet E.
Heller Ehrman LLP
Mohamed Abdel A.
LandOfFree
Formulated composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulated composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulated composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752559